Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
11 2020
Historique:
received: 04 11 2019
revised: 20 02 2020
accepted: 09 03 2020
pubmed: 11 4 2020
medline: 7 4 2021
entrez: 11 4 2020
Statut: ppublish

Résumé

Breslow thickness (BT) is the most important histopathologic factor for primary melanoma staging. BT determines the margins for wide local excision whether sentinel lymph node biopsy should be performed and subsequent melanoma staging, and patient management. The correct determination of a 0.8-mm cutoff in melanoma is important for pathologists because discrepancies leading to a change in stage can have significant clinical implications, including incorrect and/or inappropriate prognostic information, investigation, management, and follow-up. Difficulties in BT determination are mostly represented by the presence of regression or melanoma associated with a pre-existing nevus. This study aimed at investigating a molecular parameter, namely microRNA (miRNA) expression, in reference to BT assessment. Melanoma cell proliferation is influenced by miRNA dysregulation. Indeed, some miRNAs sustain and induce proliferative signals or repress growth-suppressive pathways, thereby promoting melanoma carcinogenesis. To identify the miRNAs correlating with BT, we analyzed our global miRNA expression data of 20 thin melanomas and identified two potential candidates, miR-21-5p and miR-146a-5p. We assessed the expression of these two specific miRNAs in 90 archive formalin-fixed and paraffin-embedded samples of superficially spreading melanomas (SSMs) and 25 nodular melanomas from two independent cohorts and correlated the individual and combined miRNA expression with BT and other tumor characteristics. The individually normalized expression of miR-21-5p and miR-146a-5p showed a highly significant and linear correlation with BT in SSM, and their combined expression value was more strongly correlated (Pearson's r = 0.799, 95% CI = 0.71-0.86) than their individual expressions. This correlation was not significant in nodular melanoma. In SSM, we observed that the combined miRNA expression above or below 1.5 was significantly associated with overall survival and successfully identified all patients with relapsing SSM. We concluded that the combined assessment of miR-21-5p and miR-146a-5p expression in superficially spreading melanoma, in association with BT measurement, could aid pathologists in SSM staging.

Identifiants

pubmed: 32275975
pii: S0022-202X(20)31351-8
doi: 10.1016/j.jid.2020.03.949
pii:
doi:

Substances chimiques

MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2260-2267

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Emi Dika (E)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Dermatology Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy. Electronic address: emi.dika3@unibo.it.

Mattia Riefolo (M)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Elisa Porcellini (E)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Elisabetta Broseghini (E)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Simone Ribero (S)

Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.

Rebecca Senetta (R)

Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.

Simona Osella-Abate (S)

Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.

Federica Scarfì (F)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Dermatology Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Martina Lambertini (M)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Dermatology Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Giulia Veronesi (G)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Dermatology Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Annalisa Patrizi (A)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Dermatology Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Pier Alessandro Fanti (PA)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; Dermatology Unit, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Manuela Ferracin (M)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH